Perspective Therapeutics, Inc. (NYSE:CATX) Director Buys $81,630.30 in Stock

Perspective Therapeutics, Inc. (NYSE:CATX) Director Robert F. Williamson III purchased 38,145 shares of the company’s stock in a transaction that occurred on Monday, March 31st. The shares were purchased at an average price of $2.14 per share, for a total transaction of $81,630.30. Following the purchase, the director now directly owns 108,982 shares in the company, valued at $233,221.48. The trade was a 53.85 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Perspective Therapeutics Price Performance

Perspective Therapeutics stock traded down $0.17 during trading hours on Tuesday, hitting $1.96. The company had a trading volume of 891,750 shares, compared to its average volume of 999,366. The company has a 50-day moving average price of $2.91 and a two-hundred day moving average price of $6.19. Perspective Therapeutics, Inc. has a 1 year low of $1.91 and a 1 year high of $19.05.

Analyst Ratings Changes

Several analysts have recently weighed in on CATX shares. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Perspective Therapeutics in a report on Monday. Brookline Capital Management upgraded Perspective Therapeutics to a “strong-buy” rating in a research report on Monday, March 10th. Wedbush reiterated an “outperform” rating and issued a $11.00 price target on shares of Perspective Therapeutics in a report on Wednesday, March 26th. Cantor Fitzgerald upgraded Perspective Therapeutics to a “strong-buy” rating in a report on Tuesday, March 4th. Finally, Scotiabank initiated coverage on Perspective Therapeutics in a research report on Friday, March 7th. They issued a “sector outperform” rating and a $15.00 price objective on the stock. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat.com, Perspective Therapeutics has an average rating of “Buy” and an average price target of $14.44.

Hedge Funds Weigh In On Perspective Therapeutics

A number of institutional investors have recently bought and sold shares of CATX. The Manufacturers Life Insurance Company lifted its stake in Perspective Therapeutics by 8.9% in the third quarter. The Manufacturers Life Insurance Company now owns 20,514 shares of the company’s stock valued at $274,000 after buying an additional 1,672 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of Perspective Therapeutics by 5.8% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 58,678 shares of the company’s stock valued at $783,000 after purchasing an additional 3,211 shares in the last quarter. BNP Paribas Financial Markets increased its holdings in shares of Perspective Therapeutics by 7.4% in the 4th quarter. BNP Paribas Financial Markets now owns 51,094 shares of the company’s stock worth $163,000 after acquiring an additional 3,529 shares during the period. Rhumbline Advisers boosted its stake in Perspective Therapeutics by 4.5% during the 4th quarter. Rhumbline Advisers now owns 94,992 shares of the company’s stock valued at $303,000 after purchasing an additional 4,075 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in Perspective Therapeutics by 3.4% in the 4th quarter. Bank of New York Mellon Corp now owns 143,469 shares of the company’s stock worth $458,000 after purchasing an additional 4,693 shares during the period. 54.66% of the stock is owned by hedge funds and other institutional investors.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.